Full Text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Fluorescent silica nanoparticles (SiNPs) appear to be a promising imaging platform, showing a specific subcellular localization. In the present study, we first investigated their preferential mitochondrial targeting in myeloid cells, by flow cytometry, confocal microscopy and TEM on both cells and isolated mitochondria, to acquire knowledge in imaging combined with therapeutic applications. Then, we conjugated SiNPs to one of the most used anticancer drugs, doxorubicin (DOX). As an anticancer agent, DOX has high efficacy but also an elevated systemic toxicity, causing multiple side effects. Nanostructures are usually employed to increase the drug circulation time and accumulation in target tissues, reducing undesired cytotoxicity. We tested these functionalized SiNPs (DOX-NPs) on breast cancer cell line MCF-7. We evaluated DOX-NP cytotoxicity, the effect on the cell cycle and on the expression of CD44 antigen, a molecule involved in adhesion and in tumor invasion, comparing DOX-NP to free DOX and stand-alone SiNPs. We found a specific ability to release a minor amount of CD44+ extracellular vesicles (EVs), from both CD81 negative and CD81 positive pools. Modulating the levels of CD44 at the cell surface in cancer cells is thus of great importance for disrupting the signaling pathways that favor tumor progression.

Details

Title
Fluorescent Silica Nanoparticles Targeting Mitochondria: Trafficking in Myeloid Cells and Application as Doxorubicin Delivery System in Breast Cancer Cells
Author
Sola, Federica 1 ; Montanari, Mariele 2   VIAFID ORCID Logo  ; Fiorani, Mara 2   VIAFID ORCID Logo  ; Barattini, Chiara 1 ; Ciacci, Caterina 2   VIAFID ORCID Logo  ; Burattini, Sabrina 2 ; Lopez, Daniele 3 ; Ventola, Alfredo 4 ; Zamai, Loris 2   VIAFID ORCID Logo  ; Ortolani, Claudio 2 ; Papa, Stefano 2   VIAFID ORCID Logo  ; Canonico, Barbara 2   VIAFID ORCID Logo 

 Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy; [email protected] (F.S.); [email protected] (M.M.); [email protected] (M.F.); [email protected] (C.B.); [email protected] (C.C.); [email protected] (S.B.); [email protected] (D.L.); [email protected] (L.Z.); [email protected] (C.O.); [email protected] (S.P.); AcZon s.r.l., 40050 Monte San Pietro, Italy; [email protected] 
 Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy; [email protected] (F.S.); [email protected] (M.M.); [email protected] (M.F.); [email protected] (C.B.); [email protected] (C.C.); [email protected] (S.B.); [email protected] (D.L.); [email protected] (L.Z.); [email protected] (C.O.); [email protected] (S.P.) 
 Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy; [email protected] (F.S.); [email protected] (M.M.); [email protected] (M.F.); [email protected] (C.B.); [email protected] (C.C.); [email protected] (S.B.); [email protected] (D.L.); [email protected] (L.Z.); [email protected] (C.O.); [email protected] (S.P.); Department of Pure and Applied Sciences (DiSPeA), University of Urbino Carlo Bo, 61029 Urbino, Italy 
 AcZon s.r.l., 40050 Monte San Pietro, Italy; [email protected] 
First page
3069
Publication year
2022
Publication date
2022
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2642433602
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.